We are live on ! Find out more
BGLC icon

BioNexus Gene Lab

4 hedge funds and large institutions have $558 invested in BioNexus Gene Lab in 2026 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

33% more funds holding

Funds holding: 3 → 4 (+1)

0.58% less ownership

Funds ownership: 0.6% → 0.02% (-0.58%)

98% less capital inflows, than outflows

Capital inflows: $552 | Capital outflows: $27K

Holders
4
Holders Change
+1
Holders Change %
+33.33%
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
2
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

BGLC Hedge Fund Activity: Q3 2026 in Review

4 of the 8,217 institutional investors tracked by Wall St. Rank reported a position in BioNexus Gene Lab (BGLC) for Q3 2026, worth a combined $558 — down 98% from $27.2K a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new BGLC positions and 1 closed out — a net gain of 1 holder — while 2 added to existing stakes and 0 trimmed.

The largest buyer was UBS Group, adding an estimated $319. The largest seller was HRT Financial, exiting entirely with an estimated $27K sold.

  • 4 institutional investors held BioNexus Gene Lab (BGLC) as of Q3 2026, up from 3 in Q2 2026.
  • Funds reported $558 of BioNexus Gene Lab stock for Q3 2026, down 98% quarter-over-quarter.
  • 2 funds opened new BioNexus Gene Lab positions in Q3 2026 and 1 closed out, a net change of +1 holder.
  • The largest BioNexus Gene Lab buyer in Q3 2026 was UBS Group, an estimated $319 added.
  • The largest BioNexus Gene Lab seller in Q3 2026 was HRT Financial, an estimated $27K sold.

Based on aggregated 13F filings for Q3 2026.